Clinical trials: Cardiovascular Disease Prevention
Ventricular Fibrillation, Ventricular Tachycardia
Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction
This study assesses the 18-month incidence of inappropriate shocks in subjects implanted with the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) for primary prevention of sudden cardiac death.
- Conditions
- Ventricular Fibrillation, Ventricular Tachycardia, Low Cardiac Output
- Trial name
- UNTOUCHED (NCT02433379)
- Testing
- EMBLEM S-ICD System
- Where
- 110 sites in United States, Belgium and 11 more
- Volunteers
- 1,173 people
- Sponsor
- Boston Scientific Corporation
Acute Coronary Syndrome
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots.
- Trial name
- PLATO (NCT00391872)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 672 sites in United States, Argentina and 42 more
- Volunteers
- 18,624 people
- Sponsor
- AstraZeneca
Venous Thromboembolism
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility
The primary objective was to compare the efficacy of once daily [q.d] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-VEMED (NCT00714597)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 22 sites in United States, Australia and 20 more
- Volunteers
- 421 people
- Sponsor
- Sanofi
Hypercholesteremia
Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event
Observational study to investigate the use and efficacy of CRESTOR 5 mg in reaching LDL-C target goals in both statin naïve and statin treated primary and secondary prevention patients at high risk for a cardiovascular event.
- Trial name
- NCT00347217
- Where
- 215 sites in Netherlands
- Volunteers
- 3,840 people
- Sponsor
- AstraZeneca
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Phenprocoumon for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947959
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Standard of care
- Where
- Germany
- Volunteers
- 665,533 people
- Sponsor
- Bayer
Haemophilia A
Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes.
Primary efficacy endpoint: To study whether there is a difference in the length of the bleeding free periods between infusion of FVIII that is reconstituted with 22.1, 12.6, or 4.2 mg of pegylated liposomes per kg bwt compared…
- Trial name
- NCT00245297
- Testing
- Kogenate FS, reconstituted in a suspension of liposomes
- Where
- 3 sites in Russia
- Volunteers
- 16 people
- Sponsor
- Recoly N.V.
Stroke, Secondary Prevention
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months.
- Trial name
- NCT02239120
- Testing
- optional ASA as comedication, ASA 100 mg
- Where
- 569 sites in United States, Argentina and 40 more
- Volunteers
- 5,390 people
- Sponsor
- Boehringer Ingelheim
Foot Ulcer, Diabetic
In-Home Assessment of a Smart Foot Mat for Prevention of Diabetic Foot Ulcers
The purpose of this study is to investigate the accuracy of a Smart Foot Mat for signals associated with diabetic foot ulcers in high-risk patients.
- Trial name
- NCT02647346
- Testing
- Daily use of podimetrics smart-foot mat
- Where
- 8 sites in United States
- Volunteers
- 132 people
- Sponsor
- Podimetrics, Inc.
Venous Thromboembolism
Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty
The purpose of this study is: To assess the safety and efficacy profile of ISIS-FXIRx, including incidence of bleeding and VTE, in patients undergoing total knee arthroplasty.
- Trial name
- NCT01713361
- Testing
- ISIS-FXIRx Dose #2, ISIS-FXIRx Dose #3, Enoxaparin
- Where
- 21 sites in Bulgaria, Canada and 3 more
- Volunteers
- 315 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Aneurysmal Subarachnoid Hemorrhage
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
The purpose of the study is to measure how effective and safe three different doses of the drug clazosentan are in preventing vasospasm after subarachnoid hemorrhage.
- Trial name
- CONSCIOUS-1 (NCT00111085)
- Testing
- Clazosentan 1 mg/h, Clazosentan 5 mg/h, Clazosentan 15 mg/h
- Where
- 16 sites in United States, Canada
- Volunteers
- 413 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Heart Failure, Congestive
PREVENT-HF: Prevention of Heart Failure Events With Impedance Cardiography Testing
The purpose of this study is to determine whether outpatient therapeutic management guided by impedance cardiography (ICG), in addition to standard clinical assessment, will result in a longer time in days to the first heart…
- Trial name
- NCT00409916
- Testing
- BioZ Dx
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- CardioDynamics
Heart Failure, Arrhythmias, Cardiac
Heart Failure and Sudden Cardiac Death Japan Registry
The purpose of this observational registry is to collect clinical events and outcome data in 4 different study populations (cohorts), with a majority of Japanese subjects, that are at risk of sudden cardiac death (SCD) and heart…
- Conditions
- Heart Failure, Arrhythmias, Cardiac, Sudden Cardiac Death
- Trial name
- HINODE (NCT03185832)
- Testing
- CRT-D, ICD, PM / CRT-P
- Where
- 34 sites in Japan
- Volunteers
- 354 people
- Sponsor
- Boston Scientific Corporation
Atrial Fibrillation, Stroke
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
The purpose of this study is to compare the efficacy and safety of rivaroxaban with warfarin for the prevention of blood clots in the brain (referred to as stroke) and blood clots in other parts of the body referred to as…
- Conditions
- Atrial Fibrillation, Stroke, Embolism
- Trial name
- NCT00403767
- Testing
- Rivaroxaban, Warfarin
- Where
- 932 sites in United States, Argentina and 42 more
- Volunteers
- 14,269 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Venous Thromboembolism
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the…
- Trial name
- MAGELLAN (NCT00571649)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 676 sites in United States, Argentina and 51 more
- Volunteers
- 8,101 people
- Sponsor
- Bayer
Atrial Fibrillation, Stroke Prevention
The GLACE Study: Evaluating CLAAS With ICE Guided LAA Closure
The CLAAS® device will be evaluated for safety and performance in the reduction of stroke in subjects with non-valvular atrial fibrillation under intracardiac echocardiography (ICE) imaging for left atrial appendage closure.
- Trial name
- NCT06580275
- Testing
- CLAAS
- Where
- 4 sites in Czechia, Denmark and 1 more
- Volunteers
- 67 people
- Sponsor
- Conformal Medical, Inc
Angina Pectoris
Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina
This phase III study is designed as a double blind, randomized, multi-nation, multi-center, placebo controlled clinical research, which aims to evaluate the safety and efficacy of Dantonic® (T89) in patients with chronic stable…
- Trial name
- CAESA (NCT01659580)
- Testing
- T89 high dose, T89 Low dose, Sanqi+Bingpian
- Where
- 94 sites in United States, Belarus and 5 more
- Volunteers
- 1,004 people
- Sponsor
- Tasly Pharmaceuticals, Inc.
Hypotension
Efficacy of Voluven® for the Prevention of Hypotension During Spinal Anesthesia for Cesarean Section
The aim of the study is to evaluate the efficacy of Voluven® in the prevention of maternal hypotension in women undergoing spinal anesthesia for cesarean section
- Trial name
- CAESAR (NCT00694343)
- Testing
- HES 130/0.4 (6%) in sodium chloride (solution for infusion), Ringer's Lactate solution
- Where
- 14 sites in France
- Volunteers
- 167 people
- Sponsor
- Fresenius Kabi
Hereditary Angioedema, HAE
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
- Trial name
- APeX-2 (NCT03485911)
- Testing
- BCX7353 capsules
- Where
- 47 sites in United States, Austria and 9 more
- Volunteers
- 121 people
- Sponsor
- BioCryst Pharmaceuticals
Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack)
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
This study aims to gather information to what extent patients follow the treatment regimen of low-dose aspirin for primary and secondary prevention of diseases of the heart and blood vessels.
- Conditions
- Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack), Unstable Angina, Angina
- Trial name
- PALACE (NCT04097912)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Hypertension, Diabetes
A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)
The BENEDICT study is conducted to examine the effects of an ACE inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in Type 2 diabetic patients.
- Trial name
- BENEDICT (NCT00235014)
- Testing
- trandolapril, trandolapril/verapamil, verapamil
- Volunteers
- 1,204 people
- Sponsor
- Abbott